Source link : https://www.newshealth.biz/health-news/tarlatamab-shows-promise-in-tackling-previously-treated-sclc/
The investigational bispecific T-cell engager tarlatamab achieved durable responses and clinically meaningful survival outcomes in patients with small cell lung cancer (SCLC), particularly at lower doses, according to a follow-up analysis of the phase 1 DeLLphi-300 trial. Most patients with central nervous system tumors also sustained tumor shrinkage long after receiving radiotherapy, providing “encouraging evidence” […]
Author : News Health
Publish date : 2024-03-27 12:23:07
Copyright for syndicated content belongs to the linked Source.
Categories